-
1
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-57.
-
(2009)
N Engl J Med
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
-
2
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
-
(2010)
N Engl J Med
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
Maki, R.G.6
-
3
-
-
74949133978
-
American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
-
Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6251-6266
-
-
Azzoli, C.G.1
Baker Jr., S.2
Temin, S.3
Pao, W.4
Aliff, T.5
Brahmer, J.6
-
4
-
-
22044453790
-
Erlotinib in lung cancer-molecular and clinical predictors of outcome
-
Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S, Squire J, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
-
(2005)
N Engl J Med
, vol.353
, pp. 133-144
-
-
Tsao, M.S.1
Sakurada, A.2
Cutz, J.C.3
Zhu, C.Q.4
Kamel-Reid, S.5
Squire, J.6
-
5
-
-
24944497744
-
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
-
Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5900-5909
-
-
Eberhard, D.A.1
Johnson, B.E.2
Amler, L.C.3
Goddard, A.D.4
Heldens, S.L.5
Herbst, R.S.6
-
6
-
-
79957857433
-
The BATTLE trial: Personalizing therapy for lung cancer
-
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discovery 2011;1:OF42-OF51.
-
(2011)
Cancer Discovery
, vol.1
-
-
Kim, E.S.1
Herbst, R.S.2
Wistuba, I.I.3
Lee, J.J.4
Blumenschein Jr., G.R.5
Tsao, A.6
-
7
-
-
33847666453
-
Practical Bayesian adaptive randomisation in clinical trials
-
Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007;43:859-66.
-
(2007)
Eur J Cancer
, vol.43
, pp. 859-866
-
-
Thall, P.F.1
Wathen, J.K.2
-
8
-
-
38649094549
-
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials
-
Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26:463-7.
-
(2008)
J Clin Oncol
, vol.26
, pp. 463-467
-
-
Lara Jr., P.N.1
Redman, M.W.2
Kelly, K.3
Edelman, M.J.4
Williamson, S.K.5
Crowley, J.J.6
-
9
-
-
34249810645
-
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
-
Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 2890-2896
-
-
Massarelli, E.1
Varella-Garcia, M.2
Tang, X.3
Xavier, A.C.4
Ozburn, N.C.5
Liu, D.D.6
-
10
-
-
69349088824
-
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials
-
Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-73.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5267-5273
-
-
Jackman, D.M.1
Miller, V.A.2
Cioffredi, L.A.3
Yeap, B.Y.4
Jänne, P.A.5
Riely, G.J.6
-
11
-
-
70349720358
-
Biomarker analyses from a phase III, randomized, open-label, firstline study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
-
abstract 8006
-
Fukuoka M, Wu Y, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Biomarker analyses from a phase III, randomized, open-label, firstline study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2009;27 Suppl: abstract 8006.
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Fukuoka, M.1
Wu, Y.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
-
12
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
Takada, S.4
Yamashita, Y.5
Ishikawa, S.6
-
13
-
-
79951885125
-
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
-
Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60.
-
(2010)
J Clin Oncol
, vol.28
, pp. 4953-4960
-
-
Sequist, L.V.1
Gettinger, S.2
Senzer, N.N.3
Martins, R.G.4
Jänne, P.A.5
Lilenbaum, R.6
-
14
-
-
79551709894
-
Final results from ARQ 197-209: A global randomized placebocontrolled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)
-
Paper presented at; October 8-11, Milan, Italy
-
Sequist LV, Akerley W, Brugger W, Ferrari D, Garmey EG, Gerber DE, et al. Final results from ARQ 197-209: a global randomized placebocontrolled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC). Paper presented at European Society for Medical Oncology Congress; October 8-11, 2010; Milan, Italy.
-
(2010)
European Society for Medical Oncology Congress
-
-
Sequist, L.V.1
Akerley, W.2
Brugger, W.3
Ferrari, D.4
Garmey, E.G.5
Gerber, D.E.6
-
15
-
-
78650509347
-
Randomized, phase II, multicenter, doubleblind, placebo-controlled study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer (OAM4558g)
-
Paper presented at; October 8-11, Milan, Italy
-
Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Krzakowski M, et al. Randomized, phase II, multicenter, doubleblind, placebo-controlled study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer (OAM4558g). Paper presented at European Society for Medical Oncology Congress; October 8-11, 2010; Milan, Italy.
-
(2010)
European Society for Medical Oncology Congress
-
-
Spigel, D.R.1
Ervin, T.J.2
Ramlau, R.3
Daniel, D.B.4
Goldschmidt, J.H.5
Krzakowski, M.6
|